Historically, hepatitis C virus infection has posed a barrier to cancer therapies and enrollment in clinical trials for oncology patients. Oral direct acting antivirals now allow most patients, previously considered difficult to treat to be effectively (>95% sustained virologic response) and safely cured.
|Original language||English (US)|
|Number of pages||2|
|Journal||The American Journal of Gastroenterology|
|State||Published - Feb 1 2019|
ASJC Scopus subject areas